Playback every public 2023 Asia Summit panel right here on our website.


October 19 at 3:30 pm PDT / 6:30 pm EDT

As antimicrobial resistance (AMR) continues to spread and become deadlier, potentially exacerbated by the COVID-19 pandemic, the need for new drugs has never been clearer. The antibiotic market continues to struggle from under investment and a lack of players needed to bring drugs through R&D to commercialization. While there have been positive signs in turning this around, including pull incentives and other forms of post-market support, more investment may be needed to bring drug companies back into antibiotic development. What models seem most promising? What lessons can we apply from other sectors' solutions to similar crises? And how can we foster international collaboration to jumpstart the antibiotic pipeline to combat the ever-growing threat of AMR?


Kate Sheridan
General Assignment Reporter, STAT News


Ryan Cirz
Chief Executive and Acting Chief Scientific Officer, Revagenix, Inc.

Rida Mourtada
Co-founder and Chief Scientific Officer, Lytica Therapeutics

Andrew Tomaras
Chief Scientific Officer, Forge Therapeutics

Jenny Yip
Managing Partner, Adjuvant Capital